PTC Therapeutics PTCT Sales allowance and other costs

Discontinued — last reported Q2 '20

Segments

Translarna$98.6M—

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:SalesAllowanceAndOtherRelatedCosts.

The official record: PTC Therapeutics’s 10-Q, filed August 5, 2020, on SEC EDGAR. View the filing →